Kim Margolin, MD is PI of Active and Enrolling Melanoma Clinical Trials
Kim Margolin, MD is a medical oncologist specializing in skin cancer, melanoma, metastatic cancer, with an emphasis in metastatic melanoma of the brain. Dr. Margolin is a staunch researcher, with over a hundred published articles and studies, spanning over the course of two decades. She is consistently on the cutting edge of novel treatments; her biomedical research has improved the lives of her patients in the clinic, and elsewhere.
Principal Investigator, Kim Margolin, MD is the Medical Director of the Melanoma Program at Saint John’s Cancer Institute (SJCI). Her and co-director of the Melanoma Program at SJCI, Richard Essner, MD, a surgical oncologist, recently hosted a first annual CME Melanoma Symposium in Santa Monica, Ca. View their Instagram page @santamonicamelanomasymposium to see previous, and upcoming event information. The annual event focuses on current research in the fields of melanoma and cutaneous oncology. It is open to medical professionals only. Santa Monica Melanoma Symposium will return in Spring 2023!
With a few trials underway for approval, Dr. Margolin is actively recruiting patients for the below clinical trials.
Transforming biomedical research and medicine into promising new treatments used clinically starts here at Saint John’s Cancer Institute.
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy in combination with a human monoclonal immunoglobulin G4 antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy in combination with balstilimab.
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma.
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
This is an open-label, randomized, multi-site, Phase II, an interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-PD1-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single-agent calibrator arms. Patients in single agent calibrator arms, who experience disease progression under single agent treatment, may be offered the addition of the other compound to the ongoing treatment after re-consent.
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Melanoma (MORPHEUS-MELANOMA)
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naïve patients with resectable Stage III melanoma (Cohort 1) and in patients with Stage IV melanoma (Cohort 2).
The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity and modify the participant population.
A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancer, in combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in metastatic melanoma. This study will explore the Efficacy and Safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab.
Call 310-582-7448 to participate in a clinical trial, or to learn more.
Please contact the Melanoma Center of Excellence for questions regarding diagnosis or treatments.
Dr. Margolin’s Previous Publications.